Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD

Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Liesen, Michael P., Noonan, Megan L., Ni, Pu, Agoro, Rafiou, Hum, Julia M., Clinkenbeard, Erica L., Damrath, John G., Wallace, Joseph M., Swallow, Elizabeth A., Allen, Matthew R., White, Kenneth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163801/
https://www.ncbi.nlm.nih.gov/pubmed/35656701
http://dx.doi.org/10.14814/phy2.15307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163801/
https://www.ncbi.nlm.nih.gov/pubmed/35656701
http://dx.doi.org/10.14814/phy2.15307

Ejemplares similares